Clinical Trials

Despite Negative Results, Meso Foundation Grateful for Investment Into Disease

The Meso Foundation released a statement from its executive director, Mary Hesdorffer, APRN, about AstraZeneca’s tremelimumab trial for mesothelioma.
In an AstraZeneca press release issued yesterday, the company states that “DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint […]

Read More